Drug intelligence / Profile preview

ACH24

Development stage: Discontinued
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Unknown

Overview

ACH24 is an investigational **small molecule drug** evaluated for its ability to repigment achromatic areas in patients with **vitiligo**. Developed by Aché Laboratórios Farmacêuticos, it reached Phase 3 clinical trials as a topical or oral therapy for this autoimmune skin disorder characterized by depigmentation. The pivotal Phase 3 trial for ACH24 (NCT01419964) was **withdrawn** before meaningful results could be reported. Its precise mechanism of action, modality specifics, and molecular targets have not been disclosed in public sources.

Other names: ACH24ACH-24ACH 24

Beyond the preview

Go deeper on ACH24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACH24.

Explore the full profile